» Articles » PMID: 32009915

Disrupted Social Hierarchy in Prenatally Valproate-Exposed Autistic-Like Rats

Overview
Specialty Psychology
Date 2020 Feb 4
PMID 32009915
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Autism spectrum disorder (ASD) is characterized by impaired socio-communicational function, repetitive and restricted behaviors. Valproic acid (VPA) was reported to increase the prevalence of ASD in humans as a consequence of its use during pregnancy. VPA treatment also induces autistic-like behaviors in the offspring of rats after prenatal exposure; hence it is a preclinical disease model with high translational value. In the present study, our aim was to characterize ASD relevant behaviors of socially housed, individually identified male rats in automated home cages. The natural behavior of rats was assessed by monitoring their visits to drinking bottles in an environment without human influence aiming at reducing interventional stress. Although rodents normally tend to explore their new environment, prenatally VPA-treated rats showed a drastic impairment in initial and long-term exploratory behavior throughout their stay in the automated cage. Furthermore, VPA rats displayed psychogenic polydipsia (PPD) as well as altered circadian activity. In the competitive situation of strict water deprivation controls switched to an uneven resource sharing and only a few dominant animals had access to water. In VPA animals similar hierarchy-related changes were completely absent. While the control rats secured their chance to drink with frequent reentering visits, thereby "guarding" the water resource, VPA animals did not switch to uneven sharing and displayed no evidence of guarding behavior.

Citing Articles

Gene expression differences in the olfactory bulb associated with differential social interactions and olfactory deficits in Pax6 heterozygous mice.

Daems C, Baz E, DHooge R, Callaerts-Vegh Z, Callaerts P Biol Open. 2025; 14(2).

PMID: 39902612 PMC: 11832127. DOI: 10.1242/bio.061647.


Novel automated method to assess group dynamics reveals deficits in behavioral contagion in rats with social deficits.

Smirnov K, Starkov I, Sysoeva O, Midzyanovskaya I Front Behav Neurosci. 2025; 18:1519486.

PMID: 39744143 PMC: 11688315. DOI: 10.3389/fnbeh.2024.1519486.


Effects of hyperbaric oxygen therapy on autistic behaviors and gene expression in valproic acid-exposed rats.

Mohtaj Khorassani Y, Moghimi A, Khakzad M, Fereidoni M, Hassani D, Torbati Gah J Front Neurosci. 2024; 18:1385189.

PMID: 38562305 PMC: 10982371. DOI: 10.3389/fnins.2024.1385189.


IntelliCage: the development and perspectives of a mouse- and user-friendly automated behavioral test system.

Lipp H, Krackow S, Turkes E, Benner S, Endo T, Russig H Front Behav Neurosci. 2024; 17:1270538.

PMID: 38235003 PMC: 10793385. DOI: 10.3389/fnbeh.2023.1270538.


Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder.

Roman V, Adham N, Foley A, Hanratty L, Farkas B, Lendvai B Psychopharmacology (Berl). 2021; 238(9):2381-2392.

PMID: 34264367 PMC: 8373751. DOI: 10.1007/s00213-021-05851-6.


References
1.
Panksepp J, Siviy S, Normansell L . The psychobiology of play: theoretical and methodological perspectives. Neurosci Biobehav Rev. 1984; 8(4):465-92. DOI: 10.1016/0149-7634(84)90005-8. View

2.
Nicolini C, Fahnestock M . The valproic acid-induced rodent model of autism. Exp Neurol. 2017; 299(Pt A):217-227. DOI: 10.1016/j.expneurol.2017.04.017. View

3.
Landgraf D, Joiner W, McCarthy M, Kiessling S, Barandas R, Young J . The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms. Neuropharmacology. 2016; 107:262-270. DOI: 10.1016/j.neuropharm.2016.03.047. View

4.
Gandal M, Edgar J, Ehrlichman R, Mehta M, Roberts T, Siegel S . Validating γ oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry. 2010; 68(12):1100-6. PMC: 5070466. DOI: 10.1016/j.biopsych.2010.09.031. View

5.
Loscher W . Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002; 16(10):669-94. DOI: 10.2165/00023210-200216100-00003. View